Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 7/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 5/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545142 | 0.94 | CSF1R (0.39) | EGFRCSF1RCCNT1CDK9SRC | |
| SCHEMBL29544981 | 0.93 | EGFR (0.36) | EGFRCSF1RCCNT1CDK9SRC | |
| SCHEMBL29545092 | 0.92 | EGFR (0.39) | EGFRCSF1RCCNT1CDK9SRC | |
| SCHEMBL29544572 | 0.91 | EGFR (0.40) | EGFRCSF1RCCNT1CDK9TYK2 | |
| SCHEMBL29544750 | 0.89 | EGFR (0.40) | EGFRCSF1RKDR | |
| SCHEMBL29544780 | 0.88 | EGFR (0.36) | EGFRCSF1RCCNT1CDK9TYK2 | |
| SCHEMBL29544781 | 0.86 | CCNT1 (0.34) | EGFRCSF1RCCNT1CDK9TYK2 | |
| SCHEMBL29544735 | 0.86 | CCNT1 (0.34) | EGFRCCNT1CDK9TYK2 | |
| SCHEMBL29544407 | 0.86 | CCNT1 (0.34) | EGFRCSF1RCCNT1CDK9TYK2 | |
| SCHEMBL29544652 | 0.84 | NCF1 (0.36) | EGFRCSF1RCCNT1CDK9SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |